

PRODUCTION OF *N*-ACETYLISOPENICILLIN N AND ISOPENICILLIN N  
FROM *STREPTOMYCES TOKUNONENSIS* SP. NOV.

JUN'ICHI SHOJI, HIROSHI HINOO, RYUZI SAKAZAKI, TOSHIYUKI KATO,  
KOICHI MATSUMOTO, YASUO TAKAHASHI and EIJI KONDO

Shionogi Research Laboratories, Shionogi & Co., Ltd.,  
Fukushima-ku, Osaka 553, Japan

(Received for publication August 20, 1982)

*N*-Acetylisopenicillin N was isolated from the culture broth of *Streptomyces tokunonensis* sp. nov., and identified from <sup>1</sup>H NMR spectroscopy and release of *L*- $\alpha$ -amino adipic acid by acid hydrolysis. In the course of this study, the specimen of penicillin N isolated from this strain was proved to contain a small amount of isopenicillin N by HPLC.



In the tripeptide theory<sup>1)</sup> for the biosynthesis of penicillins and cephalosporins, isopenicillin N is considered to be an important intermediate. The production of isopenicillin N from *Penicillium chrysogenum* has been shown earlier<sup>2)</sup>. The biosynthetic conversion of *L*- $\alpha$ -amino adipyl-*L*-cysteinyl-*D*-valine into isopenicillin N has been shown in the cell-free system of *Cephalosporium acremonium*<sup>3,4)</sup> and very recently the product of the cell-free reaction was isolated and directly identified by HPLC<sup>5)</sup>. However, the production of isopenicillin N from *Streptomyces* species has not been reported.

We have reported the isolation of novel carbapenem antibiotics, asparenomycins A, B and C, from *Streptomyces tokunonensis* sp. nov. whose main product is penicillin N<sup>6)</sup>. During the course of our studies for searching minor products as new active compounds from the fermentation products of this strain, we isolated *N*-acetylisopenicillin N and proved the occurrence of isopenicillin N by HPLC as will be described in this paper.

The majority of the active compounds in the fermentation products of *Streptomyces tokunonensis* sp. nov. were removed by successive adsorption and elution procedures using (1st) Amberlite IRA-68 (Rohm and Haas), (2nd) Diaion HP-20 (Mitsubishi Kasei) and then (3rd) an activated carbon, as described in the preceding paper<sup>6)</sup>. Penicillin N was recovered from the non-adsorbed fraction in the 1st step (adsorption on IRA-68) by adsorption on a Dowex 1 column (Dow Chemical) and finally purified by HPLC on a Nucleosil 10 C<sub>18</sub> column (Macherey-Nagel). The active compounds contained in the non-adsorbed fraction in the 3rd step (adsorption with an activated carbon) were recovered by adsorption on an HP-20 column. The crude powder obtained was fractionated by column chromatography with QAE Sephadex A-25 (Pharmacia Fine Chemicals) and then with HP-20 AG. When the active fraction obtained by the above was analyzed by the HPLC method described in the preceding paper<sup>6)</sup>, two unknown hydroxylamine-sensitive peaks (extinctive peaks by treatment with hydroxylamine) were observed. These were isolated by HPLC on a Nucleosil 10 C<sub>18</sub> column. One was identified with *N*-acetylisopenicillin N as described below and the other was elucidated to be a new carbapenem antibiotic, desulfo-MM 4550\*.

The sodium salt of *N*-acetylisopenicillin N is a colorless powder, soluble in water. It gives negative reaction to ninhydrin reagent. On paper electrophoresis with 50 mM phosphate buffer, pH 7.0 at 10 volt/cm for 2 hours, it migrated to the anode with R<sub>m</sub> (relative mobility to penicillin N) 1.9. It shows

\* Presented as a name, PA-31088-II, in Japan Kokai (Patent) 57-102,890, June 26, 1982

Fig. 1. IR spectrum of *N*-acetylpenicillin N (KBr).Fig. 2.  $^1\text{H}$  NMR spectrum of *N*-acetylpenicillin N ( $\text{D}_2\text{O}$ , internal reference DSS).

an end absorption in the UV spectrum and an absorption at  $1772\text{ cm}^{-1}$  attributable to  $\beta$ -lactam in the IR spectrum (Fig. 1). The  $^1\text{H}$  NMR spectrum was measured in  $\text{D}_2\text{O}$  and compared with that of penicillin N. Difference was observed in the appearance of signal d (*N*-acetyl group) and the shift of signal f to lower field (Fig. 2). The compound released approximately one mole of  $\alpha$ -aminoadipic acid by acid hydrolysis. When the amino acid was L-leucylated and analyzed by HPLC<sup>7)</sup>, only the peak of L-leucyl-L- $\alpha$ -aminoadipic acid (LL) was observed (Fig. 4).

The main product of the strain, penicillin N, was isolated and purified to show a single peak in HPLC (Fig. 3). The specimen was *N*-acetylated with *p*-nitrophenyl acetate which has been known to produce negligible racemization. When the acetyl derivative was analyzed by HPLC, a minor peak identical with that of *N*-acetylpenicillin N (natural product) was shown beside the peak of *N*-acetylpenicillin N (Fig. 3). The content of the minor peak was estimated to be approximately 5%. Furthermore, when the specimen was hydrolyzed and the chirality of the released  $\alpha$ -aminoadipic acid was examined by the above method, a small peak of (LL) was shown beside the peak of (LD) (Fig. 4). These facts clearly indicated that the specimen of penicillin N isolated from the *Streptomyces* strain contained a small amount of isopenicillin N.

NEUSS *et al.* reported a method for separation of penicillin N and isopenicillin N by HPLC<sup>5)</sup>. In the method these epimers were derivatized with a chiral compound, 2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-glucopyranosyl isothiocyanate, before injection. In our case, only *N*-acetylation made it possible to separate these epimers by HPLC. It would be considered that the bulkiness of the acetyl group enhanced the

Fig. 3. HPLC of penicillin N, *N*-acetylpenicillin N and *N*-acetylisopenicillin N.  
 Column: Nucleosil 10 C<sub>18</sub> (4×300 mm). Mobile phase: 20 mM Phosphate buffer, pH 7.0.  
 Flow rate: 2.0 ml/minute. Chart speed: 5 mm/minute. Monitored at 220 nm.  
 1) The penicillin N specimen from *S. tokunonensis* sp. nov. 2) *N*-Acetylisopenicillin N (natural product). 3) *N*-Acetyl derivative of the penicillin N specimen from *S. tokunonensis* sp. nov.





Fig. 4. HPLC of L-leucyl- $\alpha$ -aminoadipic acid (LL and LD).  
 Column: Nucleosil 10 C<sub>18</sub> (4×300 mm). Mobile phase: 20 mM Phosphate buffer, pH 7.0.  
 Flow rate: 1.0 ml/minute. Chart speed: 10 mm/minute. Monitored at 220 nm.  
 1) Preparation from *N*-acetylpenicillin N (natural product). 2) Preparation from the penicillin N specimen from *S. tokunonensis* sp. nov.



effect of the chirality of the molecules. Moreover, R. KONAKA of our laboratories devised an improved HPLC method, by which penicillin N and isopenicillin N could be separated without any derivatization.\*

Conclusively, we proved the presence of *N*-acetylisopenicillin N and isopenicillin N in the products of *S. tokunonensis* sp. nov. *N*-Acetylisopenicillin N is considered to be a shunt metabolite and isopenicillin N to be an intermediate compound before epimerization to penicillin N in the biosynthetic route in the *Streptomyces* strain. This may provide new evidence that the tripeptide theory also applies to *Streptomyces* species, and not only to fungal strains.

\* Details will be published elsewhere by R. KONAKA.

## Experimental

HPLC were obtained using a Waters 6000A pump, a Rheodyne model 7125 injector and a Japan Spectrooptics UVIDEC-100-II variable wave length UV spectrometer.  $^1\text{H}$  NMR spectrum was recorded with a Varian XL-100-12A spectrometer.

### Isolation of Penicillin N

Some 17 liters of the effluent in the adsorption procedure on an IRA-68 column with the culture filtrate of *S. tokunonensis* sp. nov. was passed through a Dowex  $1 \times 2$  ( $\text{Cl}^-$ ) column (1.3 liters) at pH 8.0. The column was eluted with 5% NaCl. Active eluate fractions by the pulp disk diffusion method on an assay plate of *E. coli* LS-1 (a super sensitive mutant to  $\beta$ -lactams) were passed through an HP-20 column (1.0 liter) at pH 5.0. The column was eluted with water and the active eluate was freeze-dried to give a crude powder (3.0 g) of penicillin N. The crude powder was chromatographed on a Pre PAK-500/ $\text{C}_{18}$  column of a High Speed Liquid Chromatograph System 500 (Waters Co., Ltd.) with 50 mM phosphate buffer, pH 7.0. The active fraction was desalted on an HP-20 column and freeze-dried to give a substantially pure preparation of penicillin N (250 mg).

A portion was further purified by HPLC on a Nucleosil 10  $\text{C}_{18}$  column ( $10 \times 300$  mm) with 20 mM phosphate buffer, pH 7.0 to afford a preparation which showed a single peak on HPLC.

### Isolation of *N*-Acetylisopenicillin N

To the non-adsorbed fraction in the adsorption procedure on an activated carbon (see text) from 100 liters of culture filtrate, NaCl was added to 5% concentration. The solution was passed through an HP-20 column (2.0 liters), and the column was eluted with water. The active eluate was freeze-dried to give a crude powder (ca. 10 g). The crude powder was chromatographed on a QAE Sephadex A-25 column ( $5.0 \times 36.0$  cm) with 0.5 M NaCl in 50 mM phosphate buffer, pH 7.0. Some 2.0 g portion was charged for a run. Two active fractions appeared. The former fraction was desalted on an HP-20 column and freeze-dried to give a powder (1.6 g), which gave two unknown hydroxylamine-sensitive peaks by the HPLC method (details of the method have been described in the preceding paper<sup>2)</sup>). When the powder was chromatographed on a Sepacool column ( $2.2 \times 90$  cm) packed with HP-20 AG (200~400 mesh) with 30 mM phosphate buffer, pH 7.0 (flow rate: 10 ml/minute, sample charge: 200 mg) monitored by a UV detector at 220 nm, two fractions each of which caused the hydroxylamine-sensitive peak, were separated. The fast eluting fraction was desalted and freeze-dried to give a crude preparation of *N*-acetylisopenicillin N (40 mg). Finally it was purified by HPLC on a Nucleosil 10  $\text{C}_{18}$  column ( $10 \times 300$  mm) with 20 mM phosphate buffer, pH 7.0. Desalination and freeze-drying of the peak fraction gave the sodium salt of *N*-acetylisopenicillin N (16 mg).

### *N*-Acetylation

Some 2.0 mg of the specimen of penicillin N isolated and purified as in the preceding section was dissolved in dimethylformamide (100  $\mu\text{l}$ ) and water (40  $\mu\text{l}$ ). *p*-Nitrophenyl acetate (1.0 mg) and triethylamine (1.25  $\mu\text{l}$ ) were added, and the solution was stirred for 16 hours at 4°C. The reaction mixture was evaporated under reduced pressure to a residue, which was dissolved in a small amount of water and applied to a short column of a Diaion HP-20 AG. The column was eluted with water and the active eluate on an assay plate of *E. coli* LS-1 was freeze-dried to give a colorless powder, which was found to be a mixture of *N*-acetylpenicillin N (main) and *N*-acetylisopenicillin N (minor) by HPLC (Fig. 3).

### Determination of Chirality of $\alpha$ -Amino adipic Acid by HPLC

Some 2 mg of *N*-acetylisopenicillin N (natural product) or the penicillin N specimen isolated from the *Streptomyces* strain was hydrolyzed with constant boiling hydrochloric acid at 110°C for 16 hours. The hydrolysate was applied to a cellulose plate (Eastman Chromatogram Sheet) and developed with *n*-butanol - acetic acid - water (4:1:2). The zone of  $\alpha$ -amino adipic acid was extracted with water and was adsorbed on a short column of Dowex  $50 \times 8$  ( $\text{NH}_4^+$ ) at pH 2.0. Elution with 0.3 N  $\text{NH}_4\text{OH}$  followed by evaporation of the eluate gave a partially purified preparation of the amino acid, whose amount was estimated by automatic amino acid analysis.

L-Leucylation was carried out in essentially the same manner as in our previous publication<sup>7)</sup>. The resulting preparations of L-leucyl- $\alpha$ -amino adipic acid were subjected to HPLC and compared with the

authentic specimens of L-leucyl-L- $\alpha$ -aminoadipic acid (LL) and L-leucyl-D- $\alpha$ -aminoadipic acid (LD). The preparation derived from N-acetylisonicillin N (natural product) exhibited a peak corresponding to (LL) and no peak of (LD). Whereas the preparation from the penicillin N specimen isolated from the *Streptomyces* strain showed a main peak corresponding to (LD) and a small peak of (LL) (Fig. 4).

#### References

- 1) ARNSTEIN, H. R. V. & D. MORRIS: The structure of a peptide, containing  $\alpha$ -aminoadipic acid, cysteine and valine, present in the mycelium of *Penicillium chrysogenum*. *Biochem. J.* 76: 357~361, 1960
- 2) FLYNN, E. H.; M. H. MCCORMICK, M. C. STAMPER, H. DEVALERIA & C. W. GODZESKI: A new natural penicillin from *Penicillium chrysogenum*. *J. Am. Chem. Soc.* 84: 4594~4595, 1962
- 3) O'SULLIVAN, J.; R. C. BLEANEY, J. A. HUDDLESTON & E. P. ABRAHAM: Incorporation of  $^3\text{H}$  from  $\delta$ -(L- $\alpha$ -amino[4,5- $^3\text{H}$ ]adipyl)-L-cysteinyl-D-[4,4- $^3\text{H}$ ]valine into isopenicillin N. *Biochem. J.* 184: 421~426, 1979
- 4) KONOMI, T.; S. HERCHEN, J. E. BALDWIN, M. YOSHIDA, N. A. HUNT & A. L. DEMAINE: Cell-free conversion of  $\delta$ -(L- $\alpha$ -aminoadipyl)-L-cysteinyl-D-valine into an antibiotic with the properties of isopenicillin N in *Cephalosporium acremonium*. *Biochem. J.* 184: 427~430, 1979
- 5) NEUSS, N.; D. M. BERRY, J. KUPKA, A. L. DEMAINE, S. W. QUEENER, D. C. DUCKWORTH & L. L. HUCKSTEP: High performance liquid chromatography (HPLC) of natural products. V. The use of HPLC in the cell-free biosynthetic conversion of  $\alpha$ -aminoadipyl-cysteinyl-valine (LLD) into isopenicillin N. *J. Antibiotics* 35: 580~584, 1982
- 6) SHOJI, J.; H. HINOO, R. SAKAZAKI, N. TSUJI, K. NAGASHIMA, K. MATSUMOTO, Y. TAKAHASHI, S. KOZUKI, T. HATTORI, E. KONDO & K. TANAKA: Asparenomycins A, B and C, new carbapenem antibiotics. II. Isolation and chemical characterization. *J. Antibiotics* 35: 15~23, 1982
- 7) KATO, T. & J. SHOJI: The structure of octapeptin D (Studies on antibiotics from the genus *Bacillus*. XXVIII). *J. Antibiotics* 33: 186~191, 1980